Free Trial

Seres Therapeutics (MCRB) Competitors

Seres Therapeutics logo
$19.48 +1.16 (+6.30%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MCRB vs. TRML, ORKA, TYRA, RZLT, ANAB, KOD, XNCR, SAGE, RAPP, and SNDL

Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Tourmaline Bio (TRML), Oruka Therapeutics (ORKA), Tyra Biosciences (TYRA), Rezolute (RZLT), AnaptysBio (ANAB), Kodiak Sciences (KOD), Xencor (XNCR), Sage Therapeutics (SAGE), Rapport Therapeutics (RAPP), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry.

Seres Therapeutics vs. Its Competitors

Seres Therapeutics (NASDAQ:MCRB) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, Tourmaline Bio had 23 more articles in the media than Seres Therapeutics. MarketBeat recorded 24 mentions for Tourmaline Bio and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.84 beat Tourmaline Bio's score of 0.39 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Seres Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tourmaline Bio
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Seres Therapeutics presently has a consensus price target of $73.67, indicating a potential upside of 278.26%. Tourmaline Bio has a consensus price target of $50.14, indicating a potential upside of 114.85%. Given Seres Therapeutics' higher possible upside, equities research analysts clearly believe Seres Therapeutics is more favorable than Tourmaline Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seres Therapeutics
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75
Tourmaline Bio
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tourmaline Bio's return on equity of -30.50% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Seres TherapeuticsN/A -350.16% -67.69%
Tourmaline Bio N/A -30.50%-29.63%

Tourmaline Bio is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres TherapeuticsN/AN/A$140K-$4.60-4.23
Tourmaline BioN/AN/A-$73.21M-$3.43-6.80

Seres Therapeutics has a beta of 2.9, indicating that its stock price is 190% more volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500.

Summary

Tourmaline Bio beats Seres Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MCRB vs. The Competition

MetricSeres TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$171.07M$3.09B$5.82B$9.75B
Dividend YieldN/A2.23%3.84%4.09%
P/E Ratio-4.2521.0131.1425.96
Price / SalesN/A396.98475.48122.90
Price / CashN/A43.0937.1558.38
Price / Book5.188.069.116.38
Net Income$140K-$54.72M$3.26B$265.56M
7 Day Performance16.69%2.30%1.94%1.81%
1 Month Performance57.18%7.21%4.91%1.14%
1 Year Performance13.23%12.85%31.21%20.98%

Seres Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MCRB
Seres Therapeutics
3.252 of 5 stars
$19.48
+6.3%
$73.67
+278.3%
+4.8%$171.07MN/A-4.25330
TRML
Tourmaline Bio
2.393 of 5 stars
$22.17
-1.8%
$50.14
+126.2%
+58.4%$579.72MN/A-6.4644
ORKA
Oruka Therapeutics
2.3469 of 5 stars
$15.25
-0.8%
$40.38
+164.8%
N/A$575.62MN/A-5.43N/AAnalyst Revision
TYRA
Tyra Biosciences
2.3759 of 5 stars
$10.81
+0.7%
$30.83
+185.2%
-48.4%$569.66MN/A-6.0720News Coverage
Analyst Forecast
RZLT
Rezolute
3.2179 of 5 stars
$6.55
+0.8%
$12.20
+86.3%
+60.0%$565.47MN/A-5.7040
ANAB
AnaptysBio
3.0484 of 5 stars
$20.02
-0.6%
$46.13
+130.4%
-46.1%$563.86M$91.28M-4.47100
KOD
Kodiak Sciences
3.2361 of 5 stars
$11.25
+6.4%
$11.75
+4.4%
+248.0%$558.33MN/A-2.9690Analyst Revision
XNCR
Xencor
3.4569 of 5 stars
$7.81
+1.7%
$26.43
+238.4%
-57.2%$547.76M$110.49M-3.25280News Coverage
Analyst Forecast
SAGE
Sage Therapeutics
3.4244 of 5 stars
$8.68
flat
$7.85
-9.6%
N/A$543.54M$41.24M-1.78690
RAPP
Rapport Therapeutics
1.7306 of 5 stars
$14.59
-0.7%
$29.50
+102.2%
-33.6%$536.70MN/A-5.84N/A
SNDL
SNDL
1.8088 of 5 stars
$2.16
+6.9%
$4.00
+85.2%
+6.2%$530.81M$671.81M-8.002,516

Related Companies and Tools


This page (NASDAQ:MCRB) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners